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Background: Prenatal exposure to perfluoroalkyl substances (PFAS) has been associated with
lower birth weight in epidemiologic studies. This association could be attributable to glomerular
filtration rate (GFR), which is related to PFAS concentration and birth weight.
Objectives: We used a physiologically based pharmacokinetic (PBPK) model of pregnancy to
assess how much of the PFAS–birth weight association observed in epidemiologic studies might be
attributable to GFR.
Methods: We modified a PBPK model to reflect the association of GFR with birth weight
(estimated from three studies of GFR and birth weight) and used it to simulate PFAS concentra arameters,
tions in maternal and cord plasma. The model was run 250,000 times, with variation in p
to simulate a population. Simulated data were analyzed to evaluate the association between
PFAS levels and birth weight due to GFR. We compared simulated estimates with those from a
meta-analysis of epidemiologic data.
Results: The reduction in birth weight for each 1-ng/mL increase in simulated cord plasma for
perfluorooctane sulfonate (PFOS) was 2.72 g (95% CI: –3.40, –2.04), and for perfluorooctanoic
acid (PFOA) was 7.13 g (95% CI: –8.46, –5.80); results based on maternal plasma at term were
similar. Results were sensitive to variations in PFAS level distributions and the strength of the
GFR–birth weight association. In comparison, our meta-analysis of epidemiologic studies suggested
that each 1-ng/mL increase in prenatal PFOS and PFOA levels was associated with 5.00 g (95% CI:
–21.66, –7.78) and 14.72 g (95% CI: –8.92, –1.09) reductions in birth weight, respectively.
Conclusion: Results of our simulations suggest that a substantial proportion of the association
between prenatal PFAS and birth weight may be attributable to confounding by GFR and that
confounding by GFR may be more important in studies with sample collection later in pregnancy.
Citation: Verner MA, Loccisano AE, Morken NH, Yoon M, Wu H, McDougall R, Maisonet M,
Marcus M, Kishi R, Miyashita C, Chen MH, Hsieh WS, Andersen ME, Clewell HJ III,
Longnecker MP. 2015. Associations of perfluoroalkyl substances (PFAS) with lower birth weight:
an evaluation of potential confounding by glomerular filtration rate using a physiologically
based pharmacokinetic model (PBPK). Environ Health Perspect 123:1317–1324; http://dx.doi.
org/10.1289/ehp.1408837

Introduction
Perfluoroalkyl substances (PFAS) are
synthetic compounds that are resistant to
degradation and have been found worldwide in environmental media and biota,
including humans. The most widely studied
PFAS are perfluorooctane sulfonate (PFOS)
and perfluorooctanoic acid (PFOA). PFOS
was an ingredient in the Scotchgard stain
repellent manufactured by 3M, but the
company decided to stop producing PFOS
in 2002 after it had been found in wildlife
and humans (Agency for Toxic Substances
and Disease Registry 2009). PFOA is a
surfactant that is used in the production of
many consumer goods, including nonstick
coating in cookware. The eight major
Environmental Health Perspectives •
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companies producing or using PFOA have
agreed to work toward eliminating emissions and product content of PFOA by 2015
[U.S. Environmental Protection Agency
(EPA) 2006]. Despite the reductions in
the production and emission of PFOS and
PFOA, these persistent compounds can still
be detected in biological samples from the
general population. For example, PFOS and
PFOA have been detected in the blood of
> 98% of participants in the 2009–2010 U.S.
National Health and Nutrition Examination
Survey (NHANES) [Centers for Disease
Control and Prevention (CDC) 2013] and
2009–2011 Canadian Health Measure
Survey (CHMS) (Health Canada 2013).
PFOS and PFOA have also been detected
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in maternal blood during pregnancy, cord
blood at delivery, and breast milk (Kim SK
et al. 2011; Olsen et al. 2009), indicating that
humans are exposed during critical prenatal
and early postnatal windows of development.
Many epidemiologic studies have reported
an association between maternal and cord
blood PFAS levels and reductions in birth
weight (Apelberg et al. 2007; Chen et al.
2012; Fei et al. 2007; Maisonet et al. 2012;
Washino et al. 2009; Whitworth et al. 2012).
Although these studies accounted for potential confounding by many variables, none
adjusted for glomerular filtration rate (GFR).
GFR, the flow rate of fluid being filtrated by
the kidneys, increases by about 50% during
the first half of pregnancy and declines slightly
during the second half of pregnancy (Gibson
1973). Two studies of GFR during pregnancy
have shown that women whose GFR fails to
rise sufficiently during pregnancy tend to have
smaller babies (Gibson 1973; Morken et al.
Address correspondence to M.-A. Verner,
Department of Occupational and Environmental
Health, School of Public Health, Université
de Montréal, 2375 chemin de la Cote-SainteCatherine, Suite 4105, Montréal, Quebec, Canada
H3T 1A8. Telephone: (514) 343-6465. E-mail:
verner.marcandre@gmail.com
Supplemental Material is available online (http://
dx.doi.org/10.1289/ehp.1408837).
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2014). On the other hand, GFR is likely to
influence the urinary excretion of xenobiotics
like PFAS. Indeed, higher blood PFAS levels
have been observed in people with lower GFR
(Shankar et al. 2011; Watkins et al. 2013).
Watkins et al. (2013) evaluated the direction of the association between PFOA and
reduced kidney function (indicated by GFR)
by comparing results obtained with measured
serum PFOA levels (which could be influenced by GFR) and estimated serum PFOA
levels (which were independent of GFR): An
association was observed only with measured
PFOA, suggesting that the association may
be a consequence of, rather than a cause of,
decreased kidney function. If so, women with
lower GFR during pregnancy would tend to
have smaller babies and higher blood PFAS
levels. This raises the possibility that GFR
confounds the association between prenatal
PFAS exposure and birth weight. To what
extent GFR influences this association has yet
to be evaluated.
In this study, we assessed how much
of the epidemiologic association between
prenatal PFOS and PFOA (PFAS thereafter)
exposure and birth weight could be attributable to confounding by GFR. We modified
a recently developed physiologically based
pharmacokinetic (PBPK) model of PFAS
during pregnancy (Loccisano et al. 2013)
to reflect the association between GFR and
PFAS levels and birth weight. The model was
run repeatedly, using Monte Carlo simulation techniques, with variation in parameters,
to simulate a population. Estimates of the
birth weight–PFAS association obtained
from simulated PFAS levels and birth
weight were subsequently compared with
estimates from a meta-analysis of existing
epidemiologic studies.

plasma, rest of fetal body, and amniotic fluid
(Figure 1). Exposure to PFAS was modeled as
an input into the maternal plasma compartment to encompass absorbed doses through
different routes. Distribution in the different
compartments was driven by blood flow rates
in and out of compartments, tissue volume,
and tissue:blood partition coefficients. PFAS
excretion in urine was modeled as a multistep process: The free (unbound) PFAS in
plasma was first filtered through the kidneys
followed by extensive active reabsorption,
with the unreabsorbed fraction continuing its
way to a storage compartment before excretion. We updated the description of placental
blood flow and fetal cardiac output according
to equations presented by Yoon et al. (2011).
The modified version of the PBPK model
code is provided in Supplemental Material,
“PBPK Model Code.” A conceptual representation with basic mass-balance differential
equations is also provided in Supplemental
Material, Figure S1.
We also modified the model so that the
initial body burden (at the beginning of pregnancy) and intake rate during pregnancy are
calculated based on an initial plasma PFAS
level [C initial (nanograms per milliliter)].
The initial amount of PFAS in the different
maternal tissues (Amountt) at each Monte
Carlo simulation (i) was computed as the
product of the initial plasma PFAS level
(Cinitial), the tissue:plasma partition coefficient
(Partitiont) and the tissue volume (Volumet):
Amountt(i) = Cinitial(i) × Partitiont(i)
× Volumet(i).
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Intake (ng/hr)(i) = Cinitial(i)
× Volume of distribution(i)
× Dosing interval
× ln(2)/Half-life,
[2]
where the volume of distribution was calculated based on partition coefficients and organ
volumes, the dosing interval was 1 hr (simulation time increment), and the half-lives of
PFOS and PFOA were 47,304 hr (5.4 years)
and 33,288 hr (3.8 years) (Olsen et al. 2007).
To parameterize the relationship between
GFR and birth weight, we performed a metaanalysis of three studies where individualspecific paired GFR and birth weight
measurements were available in the publication or made available to us (Dunlop 1981;
Gibson 1973; Morken et al. 2014). Other
studies of GFR or indicators of GFR (e.g.,
serum creatinine, serum uric acid) and birth
weight were identified but did not report
individual-specific data or regression coefficients and, consequently, could not be used
in our meta-analysis (Akahori et al. 2012;
Davison and Hytten 1974; Dunlop et al.

Dose

Rest of fetal body

Placenta

Methods
Overview. We used a PBPK model to run
Monte Carlo simulations of a study population and to generate pairs of predictions for
PFAS level and birth weight. PBPK-derived
estimates were subsequently analyzed by
linear regression. We also performed a metaanalysis of published epidemiologic studies
of prenatal PFAS exposure and birth weight
to obtain summary effect estimates. Results
obtained from simulated PFAS levels and
birth weights were compared with results
from our meta-analysis to evaluate how much
of this association might be attributable to the
influence of GFR.
The PBPK model. We modified a
published PBPK model of PFOA and PFOS
during pregnancy (Loccisano et al. 2013).
This multi-compartment model included
maternal compartments (plasma, liver, fat,
gut, skin, mammary, rest of body, kidney,
filtrate, and storage) and the placenta, fetal

[1]

Maternal PFAS intake rate during pregnancy
was estimated from initial plasma PFAS
level. To estimate maternal PFAS intake rate
during pregnancy, we assumed the initial
plasma PFAS level to be at steady state. The
hourly intake rate was calculated accordingly
using a rearrangement of a classic steady state
equation that accounts for compound-specific
half-life (hours), volume of distribution
(liters), and dosing interval (hours) (Dhillon
and Kostrzewski 2006):

Fat

Fetal
plasma
Amniotic fluid

Skin
Gut
Maternal
plasma

Liver
Mammary tissue
Rest of body
Kidney

Filtrate

Storage

Urine

Figure 1. Structure of human gestation PBPK model for PFOS and PFOA adapted from Loccisano et al.
(2013) with permission of Taylor & Francis LLC.
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1978; Duvekot et al. 1995; Knopp et al.
1985; Laughon et al. 2009). Because GFR
changes during pregnancy and the measurements were taken at different times during
pregnancy, we calculated standardized GFR
values (GFRratio) as the ratio of the observed
GFR for each subject to the mean GFR at
that gestational age [Gibson 1973 (28 gestational weeks); Dunlop 1981 (26 gestational
weeks); Morken et al. 2014 (mean, 18 gestational weeks)]. We computed the coefficient
relating birth weight to GFRratio as the inverse
variance–weighted average of the coefficient
based on regression models of data from
Gibson (1973) (n = 20), Dunlop (1981)
(n = 25), and Morken et al. (2014) (n = 953).
The raw data from these studies were either
presented in the original publication (Gibson
1973; Dunlop 1981) or were available to us
(Morken et al. 2014). In the first two studies,
GFR was measured using inulin clearance. In
the third study, GFR was estimated based on
plasma creatinine and the Cockroft–Gault
formula (Koetje et al. 2011). A separate
multiple regression model of birth weight was
fitted for each study; all models were adjusted
for gestational age at birth. The Morken et al.
(2014) data were additionally adjusted for
prepregnancy body weight and sampling
strata. Because estimation of GFR on the
basis of a single measure of plasma creatinine is known to be imprecise (Aras et al.
2012), the coefficient for GFRratio from the
Morken et al. (2014) study was deattenuated
to account for the effect of measurement error
(Willett 1990), by dividing by an intraclass
correlation coefficient of 0.76 for serum creatinine (Al-Delaimy et al. 2006) before calculating the overall inverse-variance weighted
average. Each unit increase in GFRratio was
associated with an increase in birth weight
(± SE) of 67 ± 535 g in the Dunlop (1981)
study, 1,603 ± 784 g in the Gibson (1973)
study, and 164 ± 77 g in the Morken et al.
(2014) study. The meta-analytic coefficient
was a 175.5 ± 75.9-g increase in birth weight
per unit increase in GFRratio.
We used a two-tier approach to generate
variability in GFR ratio and induce an association between GFRratio and birth weight
in Monte Carlo simulations. For each
Monte Carlo simulation (i), we first sampled
a GFR ratio value from the distribution of
GFRratio in the data of Morken et al. (2014)
[mean ± SD, 1.0 ± 0.246; range, 0.508–1.492
(± 2 SDs)]. The SD from Morken et al.
(2014) was selected because in this more
recent study, the distribution of GFR ratio
was considered to be more relevant because
of the increase in prevalence of overweight
and obesity and the correlation of GFR with
body mass index (Bosma et al. 2004). During
each simulation, the time-course of GFR
(GFRt) during pregnancy was obtained by
Environmental Health Perspectives •

volume

multiplying the reference gestational GFRt
profile (GFR as a function of time elapsed
since conception, as described in the original
PBPK model) by the sampled GFRratio:
GFRt(i) = GFRratio(i)
× Reference gestational GFRt. [3]
Then we calculated a birth weight according
to the meta-analytic regression between
GFRratio and birth weight derived from three
studies, as described above. This was accomplished by using the equation derived from
the aforementioned regression and randomly
sampling an error term based on the distribution of residuals:
Calculated birth weight (g)(i)
= Intercept + β × GFRratio(i)
		 + Residual(i),

[4]

where the intercept was 3,376 g, the β was
175.5 g per 1-unit increase in GFRratio, and
the residual was sampled from a distribution with a mean of 0 g, an SD of 441 g,
and ranging from –882 g to 882 g (± 2 SDs).
Fetal growth in the original PBPK model
was described using a time-dependent fetal
growth curve (Loccisano et al. 2013). We
adjusted this standard fetal growth curve
to match the calculated birth weight from
Equation 4. To do so, we multiplied the
standard fetal growth curve (reference fetal
weight t ) by the ratio of calculated birth
weight on the reference fetal weight t at
delivery (3,509 g). For each simulation (i),
the time-course of fetal weight (fetal weightt)
was described using the following equation:
Fetal weightt(i)
= (Calculated birth weight(i)/3,509 g)
		 × Reference fetal weightt.
[5]
PBPK model global sensitivity analysis.
Because the PBPK model used herein incorporates > 40 parameters that can vary within a
population (e.g., volume of organs, perfusion
rates, tissue:plasma partition coefficients),
we first ran a sensitivity analysis to identify
parameters with the highest relative influence on maternal plasma PFAS levels across
pregnancy and cord plasma PFAS levels at
delivery. We opted for the Morris global
method, which evaluates parameter sensitivity over a range of physiological scenarios
by taking the mean of many local sensitivity
analyses calculated over the entire parameter space, thus accounting for interactions
(McNally et al. 2011). We allowed parameters to vary between 70% and 130% of their
mean value—a 15% coefficient of variation
with bounds at ± 2 SDs. For this exercise,
we used initial maternal plasma levels of
13.02 ng/mL for PFOS and 2.53 ng/mL for
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PFOA to reflect levels in published epidemiologic studies as noted below in the “Monte
Carlo simulations” section. Sensitivity coefficients were calculated by adapting the M
code of the Morris Test included in the acslX
Optimum suite of tools (Aegis Technologies
Inc., Huntsville, AL, USA) to our study. The
set of most influential parameters—those
for which small perturbations have the most
significant effect on PFOS and PFOA levels
(coefficient within a factor of 10 of the most
sensitive model parameter at any month of
pregnancy or at delivery)—were allowed to
vary in the Monte Carlo analyses.
Assessment of PBPK model accuracy. To
assess how well the model describes the pharmacokinetics of PFAS during pregnancy, we
compared simulated plasma PFAS profiles
with observed serial levels. We identified
two reports with data that were not used by
Loccisano et al. (2013) for model development and met the following criteria: presented
two serial maternal blood PFAS levels, and
presented sufficient information on sample
collection times (Glynn et al. 2012; Monroy
et al. 2008). For each of the two reports
and each PFAS (PFOS and PFOA), we
performed 10,000 Monte Carlo iterations.
At each Monte Carlo iteration, the model
a) sampled values for sensitive parameters
identified in the global sensitivity (Table 1);
b) sampled a plasma PFAS level from the
published distributions at the first blood
sample collection time point; c) adjusted the
initial plasma level (at the time of conception), by iterative model simulations, to obtain
matching simulated and sampled PFAS level
at the time of the first blood sample collection (tolerance: 0.1%); and d) simulated a
complete pharmacokinetic profile based on
the initial plasma level. We visually compared
the distribution of simulated plasma PFAS
profiles from the Monte Carlo iterations with
the distribution of observed PFAS levels in the
second blood samples from the two reports
mentioned above.
Monte Carlo simulation. We used a
Monte Carlo procedure to simulate population PFOA and PFOS levels across pregnancy.
At each Monte Carlo iteration, the PBPK
model sampled values for sensitive parameters
identified in the global sensitivity analyses and
initial blood PFAS levels from probabilistic
distributions (Table 1) before simulation of
PFAS levels during the 9 months of pregnancy.
To be able to compare results from simulations with those from epidemiologic studies
on PFAS and birth weight included in our
meta-analysis [described below in “Metaanalysis of PFAS-birth weight epidemiologic
studies” (Apelberg et al. 2007; Chen et al.
2012; Fei et al. 2007; Hamm et al. 2010;
Maisonet et al. 2012; Washino et al. 2009;
Whitworth et al. 2012)], we used initial plasma
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PFAS distributions based on levels reported in
these studies. We calculated the mean PFOS
(13.02 ng/mL) and PFOA (2.53 ng/mL) levels
by averaging the reported mean or median
maternal blood or cord blood levels (studies
were weighted equally). These epidemiologic
studies reported different measures of spread
for blood PFAS levels (i.e., range, standard
deviation, geometric standard deviation,
interquartile range). Because these measures
of spread cannot be directly combined, we
derived a standard deviation based on coefficients of variations of 0.37 for PFOS and
0.45 for PFOA calculated using data from
Fei et al. (2007), the largest study (n = 1,399)
included in our meta-analysis (described
below). Monthly simulated maternal plasma
PFAS levels, simulated cord plasma levels at
delivery, and calculated birth weight were
collected from simulations to be used in regression models of PFAS and birth weight. We
ran 250,000 Monte Carlo iterations to achieve
convergence in the PFAS–birth weight linear
regression coefficient (β).
Sensitivity analyses. We evaluated the
influence of different assumptions on the association between PBPK-derived PFAS levels
and birth weight. In addition to analyses
noted above, we ran multiple Monte Carlo
simulations with different parameters for
PFAS distributions (higher and lower means
and standard deviations) and different coefficients for the GFR–birth weight association.
Specifically, we halved or doubled these three
parameters, one at a time. We also ran Monte
Carlo simulations with different sampling
seeds to evaluate reproducibility. We identified two studies that evaluated PFOA halflife in populations exposed through drinking
water; Brede et al. (2010) estimated a half-life
of 3.26 years, which is similar to the 3.8-year
half-life used in our study (Olsen et al. 2007),
whereas Bartell et al. (2010) estimated a
shorter half-life of 2.3 years. To evaluate the
impact of a shorter half-life on our results,
additional Monte Carlo simulations were
carried out using the half-life reported by
Bartell et al. (2010).
Meta-analysis of PFAS–birth weight epidemiologic studies. We identified human studies
published in English in 2012 or earlier using
the PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) search terms “birth weight” and
“perfluorooctane sulfonate” or “perfluoro
octanoic acid.” This identified articles with the
search terms in the title, abstract, or key words.
To be eligible for inclusion in the analysis,
the study had to have results available from
a multiple regression model of birth weight
(grams) as a function of PFOS or PFOA
in nanograms per milliliter concentration in
maternal blood from pregnancy or cord blood.
In one case (Apelberg et al. 2007), the β coefficient originally published (grams birth weight
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per interquartile increase in PFAS) was reexpressed as nanograms per milliliter by using
the interquartile distance. In three instances
we found studies that had fit models similar
to what we sought, but the published results
could not be reexpressed to obtain a reasonable approximation of what we needed. In
these cases we contacted the original authors to
obtain the coefficients of interest. Specifically,
Washino et al. (2009) and Chen et al. (2012)
had fit models with log of PFAS as the independent exposure variable, and Maisonet et al.
(2012) had fit the desired model but had not
put the β coefficients in the publication. We
used these regression coefficients to calculate
inverse variance–weighted summary β coefficients for PFOS and PFOA. A list of included
and excluded studies and a brief description of each is provided in Supplemental
Material, Table S1.

Results
PBPK modeling of PFAS levels. We first
performed a Morris global sensitivity analysis
to identify sensitive model parameters, where
a higher coefficient means greater sensitivity.
The following parameters had a sensitivity
coefficient within a factor of 10 of the most
sensitive parameter at some point during
pregnancy or at delivery: prepregnancy body
weight, liver volume, liver:plasma partition
coefficient, rest of body:plasma partition coefficient, free fraction in maternal and cord
plasma, renal reabsorption constant, and
maximum reabsorption velocity (sensitivity
coefficients are presented in Supplemental
Material, Table S2). For example, the most
sensitive parameter for PFOS levels in cord
plasma was the free fraction in fetal plasma
(global sensitivity coefficient = 0.0046). In

a one-at-a-time sensitivity analysis, a 10%
change in this parameter was associated with
an 8.9% change in simulated cord plasma
PFOS level. In comparison, a 10% change
in the liver volume (global sensitivity coefficient = 0.0003) was associated with a 0.9%
change in simulated cord plasma PFOS level.
To assess model accuracy, we simulated
maternal plasma PFAS levels based on the first
of the two serial measurements of PFAS from
two published studies (Glynn et al. 2012;
Monroy et al. 2008) and visually compared
simulated profiles with observed levels
(Figure 2). Simulated and observed PFOS
and PFOA levels declined over the course of
pregnancy in a similar fashion. However, the
model slightly underestimated the decline in
PFOA levels from the Glynn et al. (2012)
study: Mean simulated PFOA level at the time
of second blood draw was 4.3 ng/mL, whereas
mean reported level was 4.0 ng/mL.
In linear regression analyses, the association between simulated maternal and cord
plasma PFAS levels and birth weight was
dependent on the time elapsed after conception. For both PFOA (Figure 3A) and PFOS
(Figure 3B), the association between simulated
maternal plasma levels and birth weight only
appeared after the third month of pregnancy
and was strongest at the time of delivery. The
association between simulated PFOA levels
and birth weight was similar for maternal
plasma at term [β: –7.9 g; 95% confidence
interval (CI): –9.4, –6.4] and cord plasma (β:
–7.1 g; 95% CI: –8.5, –5.8). For PFOS, the
association between simulated cord plasma
levels and birth weight (β: –2.7 g; 95% CI:
–3.4, –2.0) was slightly stronger than that estimated based on simulated maternal plasma
levels (β: –1.5 g; 95% CI: –1.8, –1.1).

Table 1. Distributions of parameters used in the Monte Carlo simulations.
Parameter
Standardized glomerular filtration rate (GFRratio)a
Residual birth weight (g)b
Prepregnancy body weight (kg)c
Volume of liver as a fraction of body weightd
Liver:plasma partition coefficientd
Rest of body:plasma partition coefficientd
Free fraction in maternal plasmad
Free fraction in fetal plasmad
Resorption maximum velocity (mg/hr/kg0.75)d
Affinity constant (mg/L)d
Initial plasma PFAS levels (ng/mL)

PFAS
—
—
—
—
PFOS
PFOA
PFOS
PFOA
PFOS
PFOA
PFOS
PFOA
PFOS
PFOA
PFOS
PFOA
PFOS
PFOA

Mean ± SD
1.000 ± 0.246
0 ± 441
70.3 ± 14.3
0.026 ± 0.004
3.720 ± 0.558
2.200 ± 0.330
0.200 ± 0.030
0.120 ± 0.018
0.025 ± 0.004
0.020 ± 0.003
0.025 ± 0.004
0.020 ± 0.003
3.500 ± 0.525
10.00 ± 1.50
0.023 ± 0.003
0.055 ± 0.008
13.02 ± 4.79
2.53 ± 1.13

Minimum
0.508
–882
37.0
0.018
2.604
1.540
0.140
0.084
0.017
0.014
0.017
0.014
2.450
7.000
0.017
0.039
0.01
0.01

Maximum
1.492
882
134.0
0.034
4.836
2.860
0.260
0.156
0.033
0.026
0.033
0.026
4.550
13.000
0.029
0.071
100.00
100.00

All distributions were assumed to be normal. Values presented are arithmetic means and SDs.
aDistribution of GFR
b
ratio pooled from the three selected studies (Dunlop 1981; Gibson 1973; Morken et al. 2014). From the
GFRratio–birth weight meta-analytic regression. cDistribution of prepregnancy body weight from the Norwegian Mother
and Child Cohort Study (MoBa). dMean values taken from Loccisano et al. (2013); SDs were calculated assuming a
coefficient of variation of 15%, and bounds were set to ± 2 SD.
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different Monte Carlo sampling seeds (reproducibility). These analyses showed that the
strength of the simulated PFAS–birth weight
association (i.e., confounding by GFR) is
influenced by initial plasma PFAS level

In sensitivity analyses, we evaluated
whether the results were robust to changes
in initial plasma PFAS level distributions
(mean and SD), variations in coefficients
for the GFR–birth weight association and
Glynn et al. (2012)

Plasma PFOS level (ng/ml)
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40

30

30

20

20

10
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0

Observed data ± SD
Mean
25th–75th percentiles
5th–95th percentiles

0
0

Plasma PFOA level (ng/ml)

Monroy et al. (2008)

60

50

distributions and the GFR–birth weight coefficient: Stronger associations were obtained
with lower mean initial plasma PFAS levels
and lower SDs, and with higher GFR–birth
weight coefficients (Table 2). When more
than one parameter was changed at a time,
their influence was additive. As an example,
a lower PFOA mean (multiplier = 0.5) and
a stronger β for the GFR–birth weight association (multiplier = 2) resulted in a 23.3-g
(95% CI: –26.0, –20.6) decrease in birth
weight per nanograms per milliliter increase
in simulated cord plasma levels; conversely,
a higher PFOA mean (multiplier = 2) and
a weaker β for the GFR–birth weight association (multiplier = 0.5) resulted in a 2.4-g
(95% CI: –3.1, –1.8) decrease in birth weight
per nanograms per milliliter increase in
simulated cord plasma levels. Results from
Monte Carlo simulations using different
sampling seeds did not vary substantially,
which supports the reproducibility of
results (Table 2). Using a shorter half-life
of 2.3 years for PFOA (compared with 3.8
in main analyses) increased the strength of
the association between simulated levels in
maternal plasma at term and birth weight
by 21% (β: –9.6 g; 95% CI: –11.0, –8.2)
and between simulated levels in cord
plasma and birth weight by 14% (β: –8.1 g;
95% CI: –9.4, –6.8).
Meta-analysis of epidemiologic studies.
All studies of prenatal PFOA reported an
association with reduced birth weight,
with β coefficients ranging from –2.1 g to
–64.4 g per nanograms per milliliter increase
in PFOA levels (Figure 3A). An association
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Figure 2. Comparison of simulated versus measured levels from Glynn et al. (2012) and Monroy et al. (2008).
Distributions of simulated levels are from 10,000 Monte Carlo simulations.
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(collection time)

Beta (95% CI)

% weight

Fei et al. 2007
(9 weeks)
Maisonet et al. 2012
(15 weeks)
Hamm et al. 2010
(15.5 weeks)
Whitworth et al. 2012
(17 weeks)
Washino et al. 2012
(29 weeks)
Apelberg et al. 2007
(delivery)
Chen et al. 2012
(delivery)

Weight

–11.15 (–26.01, 3.71)

21.80

Overall

0

–14.72 (–21.66, –7.78)

100.00

–10.63 (–20.79, –0.47)

50

46.62

–34.15 (–54.88, –13.42)

11.20

–12.40 (–32.80, 8.00)

11.56

–28.40 (–60.35, 3.55)

4.71

–2.07 (–41.80, 37.65)

3.05

–64.44 (–131.78, 3.78)
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Maisonet et al. 2012
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Hamm et al. 2010
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Washino et al. 2012
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Apelberg et al. 2007
(delivery)
Chen et al. 2012
(delivery)

Weight
0
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23.95

–5.77 (–9.53, –2.02)

20.55

1.50 (–7.60, 10.60)
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–3.50 (–9.35, 2.35)

Overall

% weight

–0.46 (–2.34, 1.42)

16.19

–10.94 (–22.99, 1.10)

7.46

–13.00 (–27.85, 1.85)

5.46

–11.30 (–17.40, –5.20)

15.69

–5.00 (–8.92, –1.09)

100.00
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Maternal
0 months

0.50 (–0.90, 1.91)

Maternal
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0.10 (–0.22, 0.42)

3 months

–1.02 (–2.41, 0.38)
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–1.02 (–0.54, 0.11)
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–4.32 (–5.78, –2.87)

6 months

–0.83 (–1.17, –0.49)

–7.92 (–9.42, –6.43)
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Cord
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–7.13 (–8.46, –5.80)
–70

–50

–30

–10

10

Difference in birthweight (g)
per ng/ml increase in PFOA

–1.46 (–1.81, –1.11)
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Figure 3. Difference in birth weight (g) per 1-ng/mL increase in reported and simulated PFOA (A) and PFOS (B) levels. The size of the square represents the weight
of each study in the calculation of the overall meta-analytic association. The heterogeneity chi-square for the PFOA meta-analysis was 7.4 (not statistically
significant), and for PFOS was 20.1 (p < 0.05), both with 6 degrees of freedom. The summary beta coefficient for PFOS was from a random-effects model.
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between PFOS and reduced birth weight
was observed in six of seven studies, with β
coefficients ranging from –13.0 g to –0.5 g
per nanograms per milliliter increase in
PFOS levels (Figure 3B). The summary
β coefficients for grams birth weight
per nanograms per milliliter increase in
PFOA and PFOS levels were –14.7 g
(95% CI: –21.7, –7.8) and –5.0 g (95% CI:
–8.9, –1.1), respectively.

Discussion
In this study, we aimed to evaluate how much
of the epidemiologic association between
prenatal exposure to PFAS and reduced birth
weight might be attributable to confounding
by GFR. Results from Monte Carlo PBPK
model simulations suggest that GFR drives a
portion of this association, but not all of it,
and that its influence becomes more important with increasing gestational weeks.
When our default assumptions were
applied, the association between simulated
maternal and cord plasma PFAS levels at the
time of delivery and birth weight represented
a substantial proportion of the association
observed in our meta-analysis of epidemiologic studies. This suggests that epidemiologic studies presented herein, which have not
controlled for GFR, might have overesti
mated the influence of prenatal exposure
to PFAS on fetal growth. Our results also
suggested that GFR had less influence on
PFAS levels in maternal plasma early in
pregnancy. In a meta-regression analysis
of the epidemiologic data in Figure 3 that
we conducted (not shown), week of blood
draw was associated with a larger negative

coefficient for PFOS (–0.39 g birth weight
per nanograms per milliliter increase in PFOS
per gestational week, p < 0.01). For PFOA,
the corresponding coefficient was –0.006,
p = 0.98. Although the meta-regression results
support our hypothesis for PFOS, the lack
of support for PFOA could be attributable
to the small number of studies included, and
other sources of heterogeneity.
In light of these results, epidemiologic
studies investigating the effects of prenatal
PFAS on fetal growth should account for
the influence of GFR. Different approaches
could be considered. An option would be to
sample maternal plasma before pregnancy
or during the first trimester, when changes
in GFR have not yet influenced PFAS
significantly according to simulated results.
Statistically adjusting for GFR estimated
from plasma creatinine levels or cystatin C
levels (Tidman et al. 2008) could also help
reduce confounding by GFR. Another
approach would be to use a PBPK model to
simulate results that are specific to their study
sample collection time and PFAS distribution. Assuming the PBPK model and key
assumptions are valid, the contribution of
GFR to the observed association could be
inferred from a comparison of simulated
versus observed results. Two studies of
communities with high exposure to PFOA
have used PFOA serum levels estimated using
one-compartment pharmacokinetic model
coupled with a model for individual exposure
to evaluate the association between prenatal
exposure and birth outcomes (Savitz et al.
2012a, 2012b). Because the PFOA level estimates were not based on biological levels, the

association between estimated levels and birth
outcomes cannot be confounded by GFR.
Of note, these studies were not suggestive
of an association between prenatal PFOA
exposure and birth weight (Savitz et al.
2012b). For example, in Savitz et al. (2012b),
based on data for 4,534 births, the adjusted
change in birth weight per 100-ng/mL
increase in estimated serum PFOA was –15 g
(95% CI: –43, 14).
Our results also have implications with
regard to future meta-analyses of prenatal
PFAS and birth weight. As noted by Egger
et al. (1998), the real strength of metaanalyses is to identify factors responsible for
heterogeneity across studies. According to
our simulations, the contribution of GFR
to the association between simulated PFAS
levels and birth weight is influenced by the
timing of sample collection and PFAS level
distribution (mean and SD). A meta-analysis,
including a meta-regression, based on more
studies, and consideration of other sources of
heterogeneity, would be of interest.
Certain assumptions might have introduced bias in our study. Because individualspecific data on GFR, PFAS, and birth weight
were not available, we could evaluate the
PBPK model validity only on a population
level. Should extensive individual-specific
measurements be available during pregnancy,
the model could be further calibrated and
evaluated. Nevertheless, when we simulated plasma PFAS levels across pregnancy
in women from two studies who had their
blood levels measured twice, simulated
levels followed a decline in PFAS levels that
closely matched reported levels. Because the

Table 2. Sensitivity analyses evaluating the influence of the PFAS distribution and the strength of the GFR–birth weight association on the simulated change in
birth weight (g) per ng/mL increase in PFAS levels attributable to GFR.
Multiplier
Mean PFAS levela
PFOA
1 (main results)
2
0.5
1
1
1
1
1
1
PFOS
1 (main results)
2
0.5
1
1
1
1
1
1

Coefficient of variation
PFAS levelsb

Change in birth weight (g) per ng/mL increase in
Beta of the GFR–birth
weight associationc

Sampling seed

Maternal plasma PFAS level at delivery
[β (95% CI)]

Cord plasma PFAS level at delivery
[β (95% CI)]

1 (main results)
1
1
2
0.5
1
1
1
1

1 (main results)
1
1
1
1
2
0.5
1
1

123456789
123456789
123456789
123456789
123456789
123456789
123456789
11111
99999

–7.92 (–9.42, –6.43)
–3.96 (–4.70, –3.21)
–15.88 (–18.86, –12.89)
–3.29 (–4.19, –2.40)
–26.07 (–28.75, –23.39)
–13.40 (–16.80, –14.92)
–5.17 (–6.66, –3.68)
–8.51 (–10.01, –7.02)
–7.77 (–9.27, –6.28)

–7.13 (–8.46, –5.80)
–3.56 (–4.23, –2.90)
–14.28 (–16.95, –11.62)
–3.20 (–4.03, –2.37)
–17.59 (–19.67, –15.51)
–11.66 (–13.01, –10.31)
–4.86 (–6.18, –3.53)
–7.33 (–8.67, –5.99)
–6.89 (–8.23, –5.56)

1 (main results)
1
1
2
0.5
1
1
1
1

1 (main results)
1
1
1
1
2
0.5
1
1

123456789
123456789
123456789
123456789
123456789
123456789
123456789
11111
99999

–1.46 (–1.81, –1.11)
–0.73 (–0.91, –0.56)
–2.93 (–3.63, –2.23)
–0.54 (–0.75, –0.34)
–5.16 (–5.80, –4.51)
–2.77 (–3.12, –2.41)
–0.81 (–1.16, –0.46)
–1.80 (–2.15, –1.44)
–1.42 (–1.77, –1.07)

–2.72 (–3.40, –2.04)
–1.36 (–1.70, –1.02)
–5.45 (–6.81, –4.09)
–1.15 (–1.57, 0.73)
–6.60 (–7.65, –5.55)
–5.01 (–5.70, –4.32)
–1.57 (–2.25, –0.90)
–3.13 (–3.82, –2.45)
–2.68 (–3.36, –2.00)

aMean

values were 2.53 ng/mL for PFOA and 13.02 ng/mL for PFOS in main analyses. bCoefficients of variation were 0.446 for PFOA and 0.368 for PFOS in main analyses. cThe beta in of
the GFR–birth weight association was 175.5 g per 1-unit increase GFRratio in the main analyses.
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simulated association between PFAS and
birth weight was shown to be sensitive to
the distribution of PFAS levels, the strength
of the association between simulated PFAS
levels and birth weight from this study cannot
be compared with epidemiologic studies or
meta-analyses with a different distribution
of plasma PFAS levels. The coefficient of the
GFR–birth weight association used in the
Monte Carlo simulation was also shown to
be a sensitive parameter. Should the true association between GFR and birth weight be
stronger or weaker than the meta-analytic
relation used in this study, one would expect
the simulated association between PFAS and
birth weight to change accordingly (i.e., a
stronger GFR–birth weight association would
increase the strength of the simulated PFAS–
birth weight association and vice versa).
We also did not account for the potential
association between GFR and initial PFAS
concentration at conception. For example,
prepregnancy GFR was correlated with GFR
during pregnancy in the Gibson (1973) study
(r = 0.55–0.69) and in the Dunlop (1981)
study (r = 0.27–0.30), although correlations were statistically significant only in the
Gibson (1973) study. If prepregnancy GFR
is associated with GFR during pregnancy,
we could have underestimated the portion
of the PFAS–birth weight association that
is attributable to GFR by not accounting
for the relationship between GFR and
initial PFAS level. Also, we did not account
for correlations across model parameters in
Monte Carlo simulations, a factor that may
have increased the spread of simulated blood
PFAS levels (Burmaster and Anderson 1994).
The assumptions that the initial plasma PFAS
level is at steady state and that PFAS intake
on a body weight basis is constant throughout
pregnancy may oversimplify variations that
are expected to occur in reality.
The meta-analysis for PFOA that we
did was based on data for > 4,000 subjects.
The more formal meta-analysis by Johnson
et al. (2014) included two additional studies,
each with < 50 subjects (Fromme et al.
2010; Kim S et al. 2011). In addition, the
value we used to represent the data from the
Washino et al. (2009) study was adjusted
for more factors than was the one used by
Johnson et al. (2014), and the value we used
was closer to the null. Thus, the slightly
more negative summary in Johnson et al.
(2014) (–18.9 g/ng/mL) than in our study
(–14.7 g/ng/mL) was probably attributable
to the inclusion of the two additional studies
and the different coefficient for the Washino
et al. (2009) result. We regard the two metaanalyses as showing close agreement.
In a recent systematic review of the
literature, Lam et al. (2014) concluded that
there was sufficient evidence of an association
Environmental Health Perspectives •

volume

between prenatal PFOA and fetal growth.
Authors evaluated the hypothesis that GFR
influences the PFOA–fetal growth association
by reviewing the literature on GFR and fetal
growth. They suggested that there is insufficient evidence for an association between
maternal GFR during pregnancy and fetal
growth, and they consequently rejected the
hypothesis that GFR underlies the relationship
between PFOA and fetal growth. However,
Lam et al. (2014) did not include the study by
Morken et al. (2014) in their systematic review
of GFR and fetal growth, most likely because
the results had not been published at the time.
This new study by Morken et al. (2014), by
far the largest to date (n = 953), revealed a
significant association between estimated
GFR and birth weight. When considering
all available studies on the subject, we found
that large studies consistently demonstrated an
association between estimated GFR or indicators of GFR (e.g., serum creatinine, serum
uric acid) and birth weight [Akahori et al.
2012 (n = 120); Knopp et al. 1985 (n = 272);
Laughon et al. 2009 (n = 212); Morken et al.
2014 (n = 953)], whereas results from smaller
studies have been inconsistent [Davison and
Hytten 1974 (n = 10); Dunlop 1981 (n = 25);
Dunlop et al. 1978 (n = 34); Duvekot et al.
1995 (n = 16); Gibson 1973 (n = 21)]. Given
the new evidence, there is reason to believe a
true association exists between maternal GFR
during pregnancy and birth weight. Yet our
results, which are based on the association
between GFR and birth weight from three
studies with individual-specific paired GFR
and birth weight measurements (Dunlop
1981; Gibson 1973; Morken et al. 2014), are
not in contrast with the conclusion of Lam
et al. (2014). Rather than suggesting that GFR
is the sole driver of the association between
prenatal PFAS and birth weight, our results
indicate that a portion of the association may
be attributable to confounding by GFR, and
that effect estimates may be overpredicted
in epidemiologic studies where GFR is not
accounted for.

Conclusion
Results from our simulations suggest that
epidemiologic studies of prenatal PFAS
and birth weight may have overestimated
the strength of the association. This study
adds to existing studies demonstrating that
pharmacok inetic models can be used to
provide insight into the direction (Watkins
et al. 2013) and the strength of epidemiologic associations (Verner et al. 2013). By
combining results from epidemiologic studies
with pharmacokinetic analyses, researchers
will be able to identify underlying factors that
can positively or negatively confound associations and to estimate their contribution to
observed effect estimates.
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